Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Decent indeed though I am not interested. So for someone holding 80,000 shares they could make $800 a month and then buy 800 shares at the end of the month by taking advantage of the cheaper prices the shorting they engaged in help create. Unless they are eager to sell up their whole position even believers in the technology are going to start listening.
The longer management delays submission the more and more shareholders will be tempted to earn those biblical pieces of silver.
We already see shareholders who talk Big about NWBO and then sell out other shareholders by selling the high, helping create a pullback and then rebuying cheaper.
Specifically speculation as to whether NWBO is choosing to withhold the information from us or is legally to required to would end.
The specific nature of the legal impediment to disclosure would at least help promote more informed speculation on other points.
Given their history of being ambiguous and having limited and just as importantly, inconsistent communication there is no reason to privilege the idea that they would disclose to us but for the fact of a legal impediment This would help improve significantly damaged trust between shareholders and management.
If your speculation is right and they were not allowed to disclose the nature of the deal, then NWBO could have still communicated that more detail was not provided due to an NDA or due to a given regulation or law and in the case of a law or regulation cite the exact regulation or law that applies.
This would have properly balanced doing right by shareholders with any legal obligations.
It is almost as if the goal is to keep not inside shareholders as in the dark as possible and render it difficult to effectively assess, let alone criticize management performance because their self-appointed surrogates can endlessly play the extra “You don’t know” card, which they never seem to run out of.
Warren Buffett could always invest on his own account rather than Berkshire but does not. I don’t think his personal portfolio legally has to follow that of his fund. Now it is possible he has a position that is below a reporting threshold but then again it was possible we were going to see significant Specials revenue in the quarterly report.
Welcome to NWBO investing.
From an investor standpoint now seems to be a good time and a good price to buy and you are likely to do better than investors who have waited far longer and none of us begrudge you that.
We are likely to have a mini-catalyst this month when NWBO announces submission to MHRA and this will likely help build excitement because the clock will be started on an up or down approval decision (which I believe will be up) as NWBO has home town advantage since the company manufactures in the UK and there is no effective treatment for GBM.
A lot of investors look for the chance to jump into stocks that will have a binary catalyst any day and that should attract new investors which will help raise the SP over time up until the catalyst when we will have the potential for the kind of increase we have waited a decade for.
From a patient family member perspective the outlook is not nearly as positive. DCVax-L and Direct are great products and you should investigate then first and see if they are available via compassionate use or a trial for those close to you. Unfortunately at the rate things have been going, neither of these products is likely to be available with insurance reimbursement within a time frame for someone already diagnosed with cancer like your family member. Thus while NWBO is likely a rewarding investment you would do well to continue due diligence on the overall treatment landscape since time is probably if the essence for your relative.
Like you I am not selling and continue to average down, without doing too much (the holidays are an expensive time).
If we do not at least get an update as NWBO said they intended to provide, then some shareholders will consider selling at least part of their positions to harvest a tax loss and then rebuying once they will not get hit by the wash sale rule. While this is risky and not something I would do, in prior years where game changing news was anticipated before EOY, nothing happened. When some shareholders go through enough of those cycles, they stop being scared that NWBO will go to the moon while they are completely or partially out.
The best way to clear this matter up will be for NWBO to submit to MHRA and for MHRA to give approval. While we can already predict the fallback position that MHRA was fooled by NWBO and that FDA will be more stringent. The difference will be that money talks and the ability to project and bring in revenue in the UK (including medical tourism) through a real approval will get all kinds of attention.
Everyone gets cancer and one can ask Steve Jobs or President Biden how much wealth and power protects against cancer. Out of self-interest alone they want people to get better because all they have can be taken away by a diagnosis and they can’t have a cure for themselves without it being available for others.
Remember that NWBO indicated they would update us when the document had been submitted to the publisher.
If this happens in a timely fashion then that is a good sign. If it does not happen in the time frame laid out it is a bad sign, especially given their track record.
The publisher receiving the packet is no guarantee things will work out.
It possible for them to have more BS emerge at the publisher or for their browser.
Or when they go to submit their internet browser not to be compatible with MHRA’s website. After all, NWBO might still be using Internet explorer given how often they update their website.
Or when they go to click on the button to upload or send the email maybe the million page file size is too large so they have to get a carrier pigeon or they use a courier who is abducted by the aliens who secretly own BP.
One would think NWBO would stop at nothing to come in on time, come he’ll or high water but they would have to care about not letting their staunchest supporters and those willing to start trusting them not look like fools (again).
Thus, while there is a good chance they’ll come in on time, this time as Biosectinvestor suggests, who knows?
The gender politics of the Moonshot program are neither here nor there because as a small company that thinks all Big Pharma brings to the table is a checkbook (and not things like media and political protection) what happens with the Moonshot is not especially relevant.
We are in late 2023 and what happens with a government boondoggle ‘someday’ is as relevant as Right to Try, HE or even EAMS proved to be.
What matters is submitting to MHRA, winning approval and then pivoting on communication.
With NWBO predictions that this or that step would be shorter because of this or that reason have always been wrong and that is a legitimate cause for worry. This fear could have been lessened if the act of hitting the send button on an application to the regulator was not turned into a baroque process that required a publisher to help screw in the lightbulb.
But now we are expecting future trials managed by this same leadership team to be short?
Give everyone a break.
I am not saying that the future trials will necessarily take longer than normal but to say that they will take less time is a bold claim indeed.
This is just more speculation of the type that has blown away like leaves in autumn and winter winds each year and then the calendar turns and we start all over.
Let’s just get approved with the tech we have and that will get us the money to work whatever problems there are with Eden out. We need to stop putting the cart before the horse.
I hope you do and that your birthday month is marked by submission to MHRA and many happy returns! Happy Birthday!
I simply don’t believe it. With NWBO waiting more up front has consistently failed to reduce the length of waits down the road. Instead we wait longer than expected and then we wait longer than expected again on the next thing. That is what happens.
As for the older generation, gratification delayed so long that it only happens with one foot or, (in the case of some shareholders both humble and famous) even both feet in the grave is what I call being taken advantage of and not something to brag about but to each their own.
When management looked like they were improving in the realm of communication, transparency and execution, I was willing to set aside the hard lessons of experience, and adjust my outlook and give them space to prove they were improving in those areas.
I got attacked by critics of both the technology and the management for being foolish and even starting to believe them and those attackers were proven right and I was proven wrong on Friday the 13th.
Hopefully the Biosectinvestor Rule will hold and NWBO will meet their new time frame.
If they do, then I’ll be happy to cut back the criticism again and wait on approval.
It’s up to them.
I understand the impact Direct could have had before the potential was squandered by holding it up behind L, instead of making partnering a priority, which is one of the issues I have with management delays on L.
It’s easy to forget how long we have been authorized for Phase 2 trials and all the big talk about which indications they’d go for.
So yes, I understand about Direct all too well.
Hopefully L can be finished in time for Direct to get moving and save patients and be profitable for shareholders before a lot of them die of old age (which is not even a joke but a real danger given the demographics of many shareholders here).
What’s ridiculous is going through the same letdowns over and over and expecting management to give you a different result.
What’s your cutoff? How many extra chances do they get before you say “Yep this is an ingrained pattern of behavior that transcends individual instances.”
The tired “we don’t know” argument cannot be used because NWBO management is the reason we don’t know band are creating the doubt you say they should benefit from. They are withholding the facts.
If you wait on them to come clean about things that negatively impact shareholders, it can be years.
How many years has it been since the screening halt was imposed and how long since it was lifted? Can you link to the PR where they explained the reason for the halt?
Maybe I missed their PR. The most we got was a vague remark about good news being made into bad the last time I heard and we all know what vague remarks are worth.
The trial’s reported out TLD so being up front cannot impact it’s integrity. What excuse for withholding that information are left?
Agreed, NWBO remains a buy and will reward people who buy in at this price point. I will keep buying and holding over time.
The big suggestion of this disrupting oncology, let alone medicine in general is overblown and savors of the kind of talk that had Nikola valued more than Ford or got Theranos the funds NWBO could have really used.
What separates us from those is that the technology we gave us real and comes from outside NWBO and from Dr. Liau of UCLA.
What is true is that perhaps DCVax-L will force or encourage BP to suddenly start moving forward their own tech or tech they hurriedly buy and the explosion of competition will transform medicine in the next 10 to 15 years. NWBO investors will not see most of the resulting profits and based upon the demographics here, the revolution was too long in coming for most to truly experience the benefits.
Post August 28, 2023 NWBO management had two choices.
The first choice was that management could have truly changed their ways and promptly delivered for shareholders, breaking their old and well-worn pattern of behavior.
I though they would take that choice or why isdue the PR? For that reason I thought they deserved some space to do that and bringing up the past too much during that time would be a poor reciprocation.
If management had delivered, then it would have been more appropriate to focus on the dramatically changed present and future that their sea change in behavior would have created rather than rehashing valid criticisms about their earlier pattern of behavior..
The second choice was the choice management has taken, which was once again to have some last minute-BS that let down shareholders even though they had to know that if they failed again, many shareholders would never trust them again and would not want them to be in-charge if, post-approval another team could carry us through commercialization or to a BO.
Because NWBO, by their Friday, October 13, 2023 PR, had proved what experience had taught me about them was true and by their actions they proved that they are never going to change, there is little point in repeatedly making the case management so spectacularly made for me once and for all.
I would rather be rich than right but for now I’ll have to take the latter.
I still believe thet I am likely to (eventually) earn a decent profit from this investment and so have other old shareholders who averaged down considerably.
If I could go back in time to myself back in 2013 I would tell myself to run like hell from NWBO and buy a lot of Bitcoin early though to also be wary of fraud and learn about having multiple cold wallets.
Governance is only a recent theme they’ve taken up because the technology is so close to regulatory validation.
Would 8 or 9 mean the unexpected issue wasn’t unexpected? If so then that would mean that NWBO was not being up from in their backward looking statement.
It is but there are plenty of people addressing them and to the best of my recollection they have made little claim to be shareholders. My focus is on this one because he claims to be a shareholder. I prefer to focus on facts but they changed the rules.
Not your problem anymore, so if you were a legitimate shareholder you won’t be here after today since you’re selling up right?
Now that you’ve sold, to have credibility here (now that it’s apparently topical to discuss under the new rules) you’ll need to explain why you’re still here and there aren’t many explanations that will work for you.
Since you’ve had enough and are selling tho market opens at 9:30 am EST and your presence here will not be needed. You have your life back. You have it back even if you sold at a loss. Doubtless many other shareholders have also (much more) quietly quit over the years which is why we are at such a low SP in late 2023, supposedly on the 1 yard line.
Will you accept that the Phase 3 trial results showed efficacy if and when MHRA grants approval or are you going to pivot to claiming the FDA will never approve or even go to the extent of saying that the MHRA was wrong?
Or will it take all 4 regulators approving this product?
If so, then farewell.
I have no idea but I would have to assume that Dr. Zivic is an investor in NWBO. What are your holding by the way, since that’s apparently topical now?
This cannot be taken seriously as Dr. Zivic provides zero sourcing for his ‘optimization of Flaskworks is at hand’ remark.
Of course Dr. Zivic gets partial credit for saying ‘at hand’ instead of using one of the worn out and discredited phrases like ‘soon’ or imminent’ or ‘any day.’
If Dr. Zivic had more than just wishful thinking to back up what has the effect (though perhaps not the intention) of a pump he could give us a timeframe like ‘within 6 months’ instead of ‘at hand.’
Instead we get the usual vague happy talk that smart investors turn out and when nothing materializes, folks will still listen to him because ultimately it’s not about being good at analyzing publicly available information or having reliable sources for information not widely known, it’s about telling us what we want to hear.
If true then small wonder as anything under $1 is a good buy, regardless of what happens next month.
Each time we hear this it’s the long-term NWBO shareholders like myself who get the pain while any shorts that might be out there laugh all the way to the bank.
If empty boasting was to be believed the shorts have been frightened and desperate for a decade now. Yet here they are when they’ve had years to exit despite being desperate? Something doesn’t add up and I suspect the folks who say they’re frightened and desperate might have been wrong.
Maybe this time will be different.
We’ll see but it is important to remember that NWBO cannot just release news and expect it to raise the SP. they gave to have strong follow through including on the media side.